Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:RNLX

Renalytix (RNLX) Stock Price, News & Analysis

Renalytix logo

About Renalytix Stock (NASDAQ:RNLX)

Key Stats

Today's Range
$0.19
$0.23
50-Day Range
$0.18
$0.30
52-Week Range
$0.18
$2.40
Volume
934,400 shs
Average Volume
1.45 million shs
Market Capitalization
$17.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Buy

Company Overview

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

Receive RNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

RNLX Stock News Headlines

Renalytix Adjusts Share Capital Amid Fundraising Shortfall
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
See More Headlines

RNLX Stock Analysis - Frequently Asked Questions

Renalytix Plc (NASDAQ:RNLX) posted its earnings results on Tuesday, November, 14th. The company reported ($0.11) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.11). The business earned $0.46 million during the quarter, compared to analysts' expectations of $0.70 million.

Renalytix (RNLX) raised $156 million in an IPO on Friday, July 17th 2020. The company issued 11,000,000 shares at $14.22 per share. J.P. Morgan and Stifel acted as the underwriters for the IPO.

Renalytix's top institutional shareholders include Stifel Financial Corp (0.59%).

Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), NVIDIA (NVDA), CrowdStrike (CRWD), Broadcom (AVGO) and Meta Platforms (META).

Company Calendar

Last Earnings
11/14/2023
Today
11/21/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:RNLX
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+1,348.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-33,460,000.00
Net Margins
-1,461.60%
Pretax Margin
-1,461.42%

Debt

Sales & Book Value

Annual Sales
$2.29 million
Book Value
($0.10) per share

Miscellaneous

Free Float
63,059,000
Market Cap
$17.18 million
Optionable
Optionable
Beta
2.72
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:RNLX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners